文献速递免疫规划慢病防控与筛查卫生政策与健康促进

低收入和中低收入国家最有效人乳头瘤病毒疫苗接种策略排序:一项数学建模分析

Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis.
PubMed 文献 · Lancet Glob Health · 2025-01-01

该数学建模分析使用HPV-ADVISE模型在67个低收入和中低收入国家评估162种疫苗接种策略的效率。在基础假设下,最有效策略依次为:9岁女孩常规单剂接种后,10-14岁女孩多年龄队列单剂接种(NNV 48)、15-20岁女孩多年龄队列单剂接种(NNV 64)等。在所有情景下,最有效策略均为单剂疫苗接种女孩至20岁。

要点

  • 基础假设下效率前沿首位为10-14岁女孩多年龄队列单剂接种,NNV为48。
  • 所有情景下最有效策略均为单剂疫苗接种女孩至20岁。
  • 后续策略选择取决于国家可达接种覆盖率和宫颈癌发病率。

核心结论

  • 在低收入和中低收入国家,预防宫颈癌最有效的疫苗接种策略是单剂疫苗高覆盖率接种女孩至20岁,之后再增加男孩或为女孩提供第二剂。
  • 额外接种人群的选择将取决于国家特征和优先目标。

研究设计与样本

  • 数学建模分析,使用HPV-ADVISE模型在67个低收入和中低收入国家评估162种疫苗接种策略的效率。
  • 参数变化包括:目标人群(女孩和女性或性别中立)、年龄队列(9岁常规接种或至14岁、20岁、25岁、30岁和35岁的多年龄队列)、剂次(一剂或两剂)和接种覆盖率(40-90%),并考虑不同单剂疫苗效力和持续时间假设。
  • 效率以每预防一例宫颈癌所需剂次数(即需接种人数NNV)衡量,计算方法为增量剂次数除以100年内增量避免的宫颈癌例数。

主要发现

  • 基础假设(80%接种覆盖率、单剂疫苗非劣效、无法提高接种覆盖率)下,9岁女孩单剂常规接种后,最有效策略依次为:10-14岁女孩多年龄队列单剂接种(NNV 48);15-20岁女孩多年龄队列单剂接种(NNV 64);21-25岁女性多年龄队列两剂接种(NNV 369);9-20岁男孩常规和多年龄队列单剂接种(NNV 512);26-30岁女性多年龄队列两剂接种(NNV 640)和31-35岁女性多年龄队列两剂接种(NNV 771)。
  • 在所有调查情景(变化接种覆盖率、单剂疫苗假设和国家特征)下,最有效策略均为单剂疫苗接种女孩至20岁。
  • 次优策略取决于可达到的接种覆盖率和特定国家的宫颈癌发病率。

关键数值与推荐

  • 基础假设下效率前沿排序:10-14岁女孩单剂多年龄队列接种NNV 48;15-20岁女孩单剂多年龄队列接种NNV 64;21-25岁女性两剂多年龄队列接种NNV 369;9-20岁男孩单剂常规和多年龄队列接种NNV 512;26-30岁女性两剂多年龄队列接种NNV 640;31-35岁女性两剂多年龄队列接种NNV 771。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One-dose vaccination and increased vaccine supply provide the opportunity for low-income countries (LICs) and lower-middle-income countries (LMICs) to extend human papillomavirus (HPV) vaccination to populations other than girls aged 9-14 years targeted by routine vaccination. The aim of our study was to use mathematical modelling to identify and rank HPV vaccination strategies according to their efficiency at reducing cervical cancer in LICs and LMICs. METHODS: In this mathematical modelling analysis, we used HPV-ADVISE to model the efficiency of 162 vaccination strategies in 67 LICs and LMICs varying the following parameters: targeted populations (girls and women or gender neutral); age cohorts (routine vaccination at age 9 years or multi-age cohorts up to age 14 years, 20 years, 25 years, 30 years, and 35 years); number of doses (one or two); and vaccination coverage (40-90%), under different one-dose vaccine efficacy and duration assumptions. We measured efficiency using the number of doses needed to prevent one cervical cancer (ie, number needed to vaccinate [NNV]), obtained by dividing the incremental number of doses given by the incremental number of cervical cancers averted over 100 years. We ranked, incrementally, all strategies from most to least efficient. FINDINGS: Globally, under our base-case assumptions (80% vaccination coverage, non-inferior one-dose vaccine, and unfeasibility of increasing vaccination coverage), the model projects that, following routine vaccination of girls aged 9 years with one dose, the most efficient strategies (efficiency frontier) would be, in order: multi-age cohort vaccination of girls aged 10-14 years with one dose (NNV 48); multi-age cohort vaccination of girls aged 15-20 years with one dose (NNV 64); multi-age cohort vaccination of women aged 21-25 years with two doses (NNV 369); routine and multi-age cohort vaccination of boys aged 9-20 years with one dose (NNV 512); multi-age cohort vaccination of women aged 26-30 years (NNV 640) and 31-35 years (NNV 771) with two doses. Under all scenarios investigated (varying vaccination coverage, one-dose vaccine assumptions, and country characteristics), the model projects that the most efficient strategies would be to vaccinate girls up to age 20 years with one dose. The next most efficient strategies depend on the vaccination coverage that can be achieved and the cervical cancer incidence in a given country. INTERPRETATION: Our study suggests that the most efficient vaccination strategy to prevent cervical cancer in LICs and LMICs is to vaccinate girls aged up to 20 years with a single-dose vaccine with high vaccination coverage, before adding boys or providing a second dose to girls. The choice of additional populations to vaccinate will depend on the characteristics and prioritisation goals of a country. FUNDING: WHO, Canadian Institute of Health Research, and the Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Bénard É, Drolet M, Gingras G, et al. Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis. Lancet Glob Health. 2025. PMID: 41240953. doi:10.1016/S2214-109X(25)00376-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。